MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

ROCKVILLE, Md., Jan. 08, 2024 -- MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of...

Related Keywords

United Kingdom ,Emma Earl Freddy Crossley ,Mary Jane Elliott ,David Deuchler ,Rupert Dearden ,Maher Masoud ,Chris Welsh ,Panmure Gordon ,Nasdaq ,Exchange Commission ,Vertex Pharmaceuticals Inc ,Gilmartin Group ,Twitter ,Maxcyte Inc ,Linkedin ,Exchange Commission On ,Unaudited Fourth Quarter ,Full Year ,Platform License ,Cell Therapy ,Annual Report ,Private Securities Litigation Reform Act ,Investor Menu ,Cyte Contacts ,Joint Corporate ,Markets ,